Post-Authorisation Safety Study (PASS) MA25101: An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ARROVEN)

Study protocol

Initial protocol

MA25101_Post-Authorisation Safety Study (PASS)_Amendment 2 w MPI change

English (986.79 KB - PDF) View document

Updated protocol

MA25101 Protocol Amend 4 2017-01-27

First published: 22/02/2024

English (472.02 KB - PDF) View document

Study results

FINAL Takeda ARROVEN PASS_CSR_v3.0_27Nov2019

English (1.1 MB - PDF) View document

MA25101 - Abstract

English (693.93 KB - PDF) View document

Study report

Other information

Secondary tabs